亿帆医药：关于获得药品注册证书的公告

Group 1 - The core point of the article is that Yifan Pharmaceutical announced the approval of its subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. for the drug registration certificate of injectable colistin sulfate B by the National Medical Products Administration on January 22, 2026 [2] Group 2 - The approval signifies a significant milestone for the company in expanding its product portfolio in the biopharmaceutical sector [2] - This development may enhance the company's competitive position in the market for injectable antibiotics [2] - The registration certificate is expected to facilitate the commercialization of the product, potentially leading to increased revenue streams for the company [2]